These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 37740521

  • 1. Use of molidustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, in chronic kidney disease-associated anemia in cats.
    Charles S, Süssenberger R, Settje T, Langston C, Lainesse C.
    J Vet Intern Med; 2024; 38(1):197-204. PubMed ID: 37740521
    [Abstract] [Full Text] [Related]

  • 2. Pharmacodynamic effects of molidustat on erythropoiesis in healthy cats.
    Boegel A, Flamme I, Krebber R, Settje T, Schmidt F, Kruedewagen E, Mangold-Gehring S, Lainesse C, Moritz A, Beddies G.
    J Vet Intern Med; 2024; 38(1):381-387. PubMed ID: 37994487
    [Abstract] [Full Text] [Related]

  • 3. First-in-man-proof of concept study with molidustat: a novel selective oral HIF-prolyl hydroxylase inhibitor for the treatment of renal anaemia.
    Böttcher M, Lentini S, Arens ER, Kaiser A, van der Mey D, Thuss U, Kubitza D, Wensing G.
    Br J Clin Pharmacol; 2018 Jul; 84(7):1557-1565. PubMed ID: 29575006
    [Abstract] [Full Text] [Related]

  • 4. Iron Regulation by Molidustat, a Daily Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, in Patients with Chronic Kidney Disease.
    Akizawa T, Macdougall IC, Berns JS, Yamamoto H, Taguchi M, Iekushi K, Bernhardt T.
    Nephron; 2019 Jul; 143(4):243-254. PubMed ID: 31387097
    [Abstract] [Full Text] [Related]

  • 5. A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial.
    Brigandi RA, Johnson B, Oei C, Westerman M, Olbina G, de Zoysa J, Roger SD, Sahay M, Cross N, McMahon L, Guptha V, Smolyarchuk EA, Singh N, Russ SF, Kumar S, PHI112844 Investigators.
    Am J Kidney Dis; 2016 Jun; 67(6):861-71. PubMed ID: 26827289
    [Abstract] [Full Text] [Related]

  • 6. Effects of Molidustat in the Treatment of Anemia in CKD.
    Macdougall IC, Akizawa T, Berns JS, Bernhardt T, Krueger T.
    Clin J Am Soc Nephrol; 2019 Jan 07; 14(1):28-39. PubMed ID: 30559105
    [Abstract] [Full Text] [Related]

  • 7. Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study.
    Yamamoto H, Nobori K, Matsuda Y, Hayashi Y, Hayasaki T, Akizawa T.
    Am J Nephrol; 2021 Jan 07; 52(10-11):884-893. PubMed ID: 34569482
    [Abstract] [Full Text] [Related]

  • 8. Discovery of Molidustat (BAY 85-3934): A Small-Molecule Oral HIF-Prolyl Hydroxylase (HIF-PH) Inhibitor for the Treatment of Renal Anemia.
    Beck H, Jeske M, Thede K, Stoll F, Flamme I, Akbaba M, Ergüden JK, Karig G, Keldenich J, Oehme F, Militzer HC, Hartung IV, Thuss U.
    ChemMedChem; 2018 May 23; 13(10):988-1003. PubMed ID: 29485740
    [Abstract] [Full Text] [Related]

  • 9. Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effects.
    Flamme I, Oehme F, Ellinghaus P, Jeske M, Keldenich J, Thuss U.
    PLoS One; 2014 May 23; 9(11):e111838. PubMed ID: 25392999
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and Safety of Molidustat for Anemia in ESA-Naive Nondialysis Patients: A Randomized, Phase 3 Trial.
    Yamamoto H, Nobori K, Matsuda Y, Hayashi Y, Hayasaki T, Akizawa T.
    Am J Nephrol; 2021 May 23; 52(10-11):871-883. PubMed ID: 34569489
    [Abstract] [Full Text] [Related]

  • 11. The drug-specific properties of hypoxia-inducible factor-prolyl hydroxylase inhibitors in mice reveal a significant contribution of the kidney compared to the liver to erythropoietin induction.
    Nakai T, Saigusa D, Kato K, Fukuuchi T, Koshiba S, Yamamoto M, Suzuki N.
    Life Sci; 2024 Jun 01; 346():122641. PubMed ID: 38614299
    [Abstract] [Full Text] [Related]

  • 12. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD.
    Gupta N, Wish JB.
    Am J Kidney Dis; 2017 Jun 01; 69(6):815-826. PubMed ID: 28242135
    [Abstract] [Full Text] [Related]

  • 13. Effects of hypoxia-inducible factor-prolyl hydroxylase inhibitors vs. erythropoiesis-stimulating agents on iron metabolism in non-dialysis-dependent anemic patients with CKD: A network meta-analysis.
    Yang J, Xing J, Zhu X, Xie X, Wang L, Zhang X.
    Front Endocrinol (Lausanne); 2023 Jun 01; 14():1131516. PubMed ID: 37008953
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Long-Term Efficacy and Safety of Molidustat for Anemia in Chronic Kidney Disease: DIALOGUE Extension Studies.
    Akizawa T, Macdougall IC, Berns JS, Bernhardt T, Staedtler G, Taguchi M, Iekushi K, Krueger T.
    Am J Nephrol; 2019 Jun 01; 49(4):271-280. PubMed ID: 30852574
    [Abstract] [Full Text] [Related]

  • 16. Effects of post-renal anemia treatment with the HIF-PHD inhibitor molidustat on adenine-induced renal anemia and kidney disease in mice.
    Li L, Nakano D, Zhang A, Kittikulsuth W, Morisawa N, Ohsaki H, Suzuki N, Yamamoto M, Nishiyama A.
    J Pharmacol Sci; 2020 Dec 01; 144(4):229-236. PubMed ID: 33070842
    [Abstract] [Full Text] [Related]

  • 17. Hypoxia-Inducible Factor-Prolyl Hydroxylase Domain Inhibitors to Treat Anemia in Chronic Kidney Disease.
    Sakashita M, Tanaka T, Nangaku M.
    Contrib Nephrol; 2019 Dec 01; 198():112-123. PubMed ID: 30991411
    [Abstract] [Full Text] [Related]

  • 18. Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of anemia in chronic kidney disease.
    Kurata Y, Tanaka T, Nangaku M.
    Curr Opin Nephrol Hypertens; 2020 Jul 01; 29(4):414-422. PubMed ID: 32452915
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Preclinical Characterization of Vadadustat (AKB-6548), an Oral Small Molecule Hypoxia-Inducible Factor Prolyl-4-Hydroxylase Inhibitor, for the Potential Treatment of Renal Anemia.
    Zuk A, Si Z, Loi S, Bommegowda S, Hoivik D, Danthi S, Molnar G, Csizmadia V, Rabinowitz M.
    J Pharmacol Exp Ther; 2022 Oct 01; 383(1):11-24. PubMed ID: 35926869
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.